Abstract / Summary
Background: Oral nicotinamide has been proposed as a chemoprevention strategy to reduce new keratinocyte carcinomas in people with a history of skin cancer, but its effect may differ between immunocompetent patients and transplant recipients.
Objective: To evaluate the effectiveness and safety of oral nicotinamide for the secondary prevention of cutaneous squamous cell carcinoma and other keratinocyte carcinoma-related outcomes in adults with a history of skin cancer.
Methods: We conducted a systematic review following PRISMA 2020. We searched PubMed/MEDLINE, Embase, and LILACS through the Virtual Health Library from inception to May 30, 2026. We included comparative studies (randomized clinical trials and controlled nonrandomized studies) evaluating oral nicotinamide versus placebo, no treatment, usual care, or another preventive strategy. Risk of bias was assessed with RoB 2 for randomized trials and ROBINS-I for nonrandomized studies, and the certainty of evidence was assessed with GRADE. We performed a narrative synthesis and an exploratory random-effects meta-analysis of randomized trials when clinically appropriate; effect measures were rate ratios for randomized trials and hazard ratios for the observational cohort. Randomized and nonrandomized designs were not statistically pooled together.
Results: We identified 1076 records; after removing 151 duplicates, 925 records were screened, 17 full texts were assessed, and 5 studies were included: 4 randomized clinical trials and 1 large retrospective cohort. In high-risk immunocompetent adults, the benefit signal was driven by a single pivotal randomized trial (ONTRAC; n = 386), in which nicotinamide reduced new nonmelanoma skin cancers (rate ratio, 0.77; 95% CI, 0.62-0.96). In transplant recipients, the main exploratory meta-analysis of two randomized trials (n = 180) showed no significant reduction in total keratinocyte carcinoma/nonmelanoma skin cancer (pooled rate ratio, 0.97; 95% CI, 0.77-1.22; I 2 = 0.0%), cSCC/SCC (0.90; 95% CI, 0.65-1.25; 2 trials), or basal cell carcinoma (0.80; 95% CI, 0.20-3.18; 2 trials). A large retrospective cohort (Breglio et al.; 33,822 patients) reported an overall 14% reduction in skin cancer (hazard ratio, 0.86; 95% CI, 0.83-0.89) that was greatest for cSCC and greatest when nicotinamide was started after the first skin cancer, but there was no overall benefit in transplant recipients (hazard ratio, 1.02; 95% CI, 0.84-1.25). Certainty was low or very low for the transplant-recipient outcomes.
Conclusions: In high-risk immunocompetent adults, oral nicotinamide may reduce new nonmelanoma skin cancers during active treatment, but this conclusion rests predominantly on one large randomized trial and should be regarded as provisional. In transplant recipients, the randomized evidence does not demonstrate a significant benefit, a finding concordant with the overall null result in the large observational cohort. An observational signal favoring early initiation is hypothesis-generating and requires prospective confirmation.